The study is led by Professor Shen Lin of Peking University Cancer Hospital. In the safety run‑in stage, Opamtistomig in combination with chemotherapy demonstrated encouraging efficacy signals in ...
Nanjing Leads Biolabs (SEHK:9887) reported that China's National Medical Products Administration accepted its NDA for ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization ...
The U.S. Food and Drug Administration (FDA) has approved two treatment combinations containing Ziihera (zanidatamab-hrii) for ...
Durvalumab targets PD-L1, a key immune checkpoint. Normally, antigen-presenting cells (APCs) recognize cancer cell antigens and activate cytotoxic T cells, which travel to the tumor site for ...
A new review article outlines the latest research and results into programmed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors for the treatment of myelodysplastic syndromes (MDS) ...
PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...
Personalized recommendations for patients with non–small cell lung cancer with squamous histology could benefit from research on treatment choice and biomarkers, noted Blythe Adamson, PhD, MPH, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results